drugset
drugset / Trial / NCT04361812

Comparison of Pharmacokinetics and Safety of HS632 and Xolair® With a Single Injection

NCT04361812 ↗

Phase 1 Terminated 1 enrolled BioRay Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the bioequivalence of HS632 and Omalizumab (Xolair®) in a single subcutaneous administration in healthy subjects.

Timeline

Start
2020-10-15
Primary completion
2021-12-31
Completion
2021-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject HS632 Monoclonal antibody 150 mg Subcutaneous
Comparator Omalizumab Monoclonal antibody 150 mg Subcutaneous

Indications

No indication recorded.